Results 131 to 140 of about 12,413,959 (307)

Five‐Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction To enhance the treatment quality in haemophilia centres (HC), the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research (GTH) started in 2017 the development of guidelines to define the structural and process quality of HC, essentially related to the EUHANET guidelines.
Hermann Eichler   +18 more
wiley   +1 more source

Mutation analysis and characterisation of F9 gene in haemophilia- B population of India. [PDF]

open access: yesBlood Res, 2021
Kulkarni S   +8 more
europepmc   +1 more source

Haemophilia B case report

open access: yesLiječnički vjesnik, 2019
Haemophilia B (Christmas disease) is a rare genetic coagulopathy. It is caused by deficiency of coagulation factor IX due to inherited mutation of gene located on X chromosome. Disease commonly affects male population and its presentation depends on severity of clotting protein shortage.
openaire   +2 more sources

Genetic analysis in a female manifesting haemophilia B [PDF]

open access: bronze, 1994
Stephen Palmer   +3 more
openalex   +1 more source

Low‐Load Quadriceps Strengthening With Blood Flow Restriction in Adults With Haemophilic Knee Arthropathy: A Randomised Controlled Trial

open access: yesHaemophilia, EarlyView.
Abstract Introduction Haemophilic knee arthropathy leads to a reduction in muscle mass and strength. Blood flow restriction (BFR) involves the application of a compressive cuff that enables strength training with reduced loads. Objective To evaluate safety as the primary outcome and the efficacy (muscle strength and activation, functional capacity and ...
Mar Villalón‐González   +4 more
wiley   +1 more source

florio HAEMO—A Digital Medical Device for Monitoring of Treatment, Symptoms and Physical Activities for People Living With Haemophilia

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Despite therapeutic achievements in haemophilia care, there is still the need to monitor and define personal treatment outcomes and document results to achieve the best possible care. Hence, a need for unbiased, timely and comprehensive real‐world information exists to support informed shared decision‐making regarding treatment ...
Christoph Königs   +9 more
wiley   +1 more source

Preclinical development of plant-based oral immune modulatory therapy for haemophilia B. [PDF]

open access: yesPlant Biotechnol J, 2021
Srinivasan A   +6 more
europepmc   +1 more source

Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre [PDF]

open access: bronze, 2010
Davi de Podestá Haje   +6 more
openalex   +1 more source

Investigation of the Suitability of the ROTEM Assay to Measure Coagulation Potential in Blood From Patients on Concizumab Prophylaxis

open access: yesHaemophilia, EarlyView.
ABSTRACT Background Rotational thromboelastometry (ROTEM) aims to measure the coagulation potential in whole blood. Concizumab, an anti‐tissue factor pathway inhibitor (TFPI) antibody for prophylaxis in haemophilia, enhances tissue factor (TF)‐initiated coagulation by preventing inhibition of activated factor X (FXa), thus increasing thrombin ...
Hermann Eichler   +9 more
wiley   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

open access: yesHaemophilia, EarlyView.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy